Preadaptation of simian immunodeficiency virus SIVsmm facilitated Env-mediated counteraction of human tetherin by human immunodeficiency virus type 2

Journal of Virology

Volumn 92, Issue 18, 2018, Pages

  Heusinger, Elena ^a   Deppe, Katja ^a   Sette, Paola ^b   Krapp, Christian ^a,d   Kmiec, Dorota ^a   Kluge, Silvia F ^a   Marx, Preston A ^c   Apetrei, Cristian ^b   Kirchhoff, Frank ^a   Sauter, Daniel ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

Env; HIV 2; Nef; SIVsmm; Tetherin

Indexed keywords

BONE MARROW STROMAL ANTIGEN 2; CD3 ANTIGEN; CD4 ANTIGEN; NEF PROTEIN; VIRUS ENVELOPE PROTEIN; BST2 PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LEUKOCYTE ANTIGEN;

ARTICLE; CELL LINE; CONTROLLED STUDY; EMBRYO; GENETIC TRAIT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 2; NONHUMAN; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS RECOMBINANT; VIRUS RELEASE; VIRUS TRANSMISSION; ZOONOSIS; ANTAGONISTS AND INHIBITORS; GENETICS; HOST PATHOGEN INTERACTION; METABOLISM;

ANTIGENS, CD; CD3 COMPLEX; CD4 ANTIGENS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE PRODUCTS, NEF; GPI-LINKED PROTEINS; HIV-2; HOST-PATHOGEN INTERACTIONS; HUMANS; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 85053021004     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00276-18     Document Type: Article

References (121)

1. Visseaux B, Damond F, Matheron S, Descamps D, Charpentier C. 2016. Hiv-2 molecular epidemiology. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis 46:233-240.
2. Arien KK, Abraha A, Quinones-Mateu ME, Kestens L, Vanham G, Arts EJ. 2005. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J Virol 79:8979-8990. https://doi.org/10.1128/JVI.79.14.8979-8990.2005.
3. De Cock KM, Adjorlolo G, Ekpini E, Sibailly T, Kouadio J, Maran M, Brattegaard K, Vetter KM, Doorly R, Gayle HD. 1993. Epidemiology and transmission of HIV-2: why there is no HIV-2 pandemic. JAMA 270:2083-2086.
4. Gao F, Yue L, Robertson DL, Hill SC, Hui H, Biggar RJ, Neequaye AE, Whelan TM, Ho DD, Shaw GM. 1994. Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J Virol 68:7433-7447.
5. Smith SM, Christian D, de Lame V, Shah U, Austin L, Gautam R, Gautam A, Apetrei C, Marx PA. 2008. Isolation of a new HIV-2 group in the US. Retrovirology 5:103. https://doi.org/10.1186/1742-4690-5-103.
6. Chen Z, Luckay A, Sodora DL, Telfer P, Reed P, Gettie A, Kanu JM, Sadek RF, Yee J, Ho DD, Zhang L, Marx PA. 1997. Human immunodeficiency virus type 2 (HIV-2) seroprevalence and characterization of a distinct HIV-2 genetic subtype from the natural range of simian immunodeficiency virus-infected sooty mangabeys. J Virol 71:3953-3960.
7. Brennan CA, Yamaguchi J, Vallari AS, Hickman RK, Devare SG. 1997. Genetic variation in human immunodeficiency virus type 2: identification of a unique variant from human plasma. AIDS Res Hum Retrovir 13:401-404. https://doi.org/10.1089/aid.1997.13.401.
8. Yamaguchi J, Devare SG, Brennan CA. 2000. Identification of a new HIV-2 subtype based on phylogenetic analysis of full-length genomic sequence. AIDS Res Hum Retrovir 16:925-930. https://doi.org/10.1089/ 08892220050042864.
9. Damond F, Worobey M, Campa P, Farfara I, Colin G, Matheron S, Brun-Vezinet F, Robertson DL, Simon F. 2004. Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classification. AIDS Res Hum Retrovir 20:666-672. https://doi.org/10.1089/ 0889222041217392.
10. Visseaux B, Hurtado-Nedelec M, Charpentier C, Collin G, Storto A, Matheron S, Larrouy L, Damond F, Brun-Vezinet F, Descamps D, ANRS CO 05 HIV-2 Cohort. 2012. Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool. J Infect Dis 205:111-120. https://doi.org/10.1093/infdis/jir698.
11. Ayouba A, Akoua-Koffi C, Calvignac-Spencer S, Esteban A, Locatelli S, Li H, Li Y, Hahn BH, Delaporte E, Leendertz FH, Peeters M. 2013. Evidence for continuing cross-species transmission of SIVsmm to humans: characterization of a new HIV-2 lineage in rural Cote d'Ivoire. AIDS 27: 2488-2491. https://doi.org/10.1097/01.aids.0000432443.22684.50.
12. Ibe S, Yokomaku Y, Shiino T, Tanaka R, Hattori J, Fujisaki S, Iwatani Y, Mamiya N, Utsumi M, Kato S, Hamaguchi M, Sugiura W. 2010. HIV-2 CRF01-AB: first circulating recombinant form of HIV-2. J Acquir Immune Defic Syndr 54:241-247. https://doi.org/10.1097/QAI.0b013e3181dc98c1.
13. Lemey P, Pybus OG, Wang B, Saksena NK, Salemi M, Vandamme A-M. 2003. Tracing the origin and history of the HIV-2 epidemic. Proc Natl Acad Sci U S A 100:6588-6592. https://doi.org/10.1073/pnas.0936469100.
14. Gao F, Yue L, White AT, Pappas PG, Barchue J, Hanson AP, Greene BM, Sharp PM, Shaw GM, Hahn BH. 1992. Human infection by genetically diverse SIVSM-related HIV-2 in west Africa. Nature 358: 495-499. https://doi.org/10.1038/358495a0.
15. Yamaguchi J, Vallari A, Ndembi N, Coffey R, Ngansop C, Mbanya D, Kaptue L, Gurtler LG, Devare SG, Brennan CA. 2008. HIV type 2 intergroup recombinant identified in Cameroon. AIDS Res Hum Retrovir 24:86-91. https://doi.org/10.1089/aid.2007.0190.
16. Ndembi N, Abraha A, Pilch H, Ichimura H, Mbanya D, Kaptue L, Salata R, Arts EJ. 2008. Molecular characterization of human immunodeficiency virus type 1 (HIV-1) and HIV-2 in Yaounde, Cameroon: evidence of major drug resistance mutations in newly diagnosed patients infected with subtypes other than subtype B. J Clin Microbiol 46:177-184. https://doi.org/10.1128/JCM.00428-07.
17. Ho DD, Lee S, Moudgil T, Kerndt PR. 1990. HIV-2 in Los Angeles. AIDS 4:1301-1302. https://doi.org/10.1097/00002030-199012000-00028.
18. Hirsch VM, Olmsted RA, Murphey-Corb M, Purcell RH, Johnson PR. 1989. An African primate lentivirus (SIVsm) closely related to HIV-2. Nature 339:389-392. https://doi.org/10.1038/339389a0.
19. Sousa JD, Temudo MP, Hewlett BS, Camacho RJ, Muller V, Vandamme A-M. 2016. Male circumcision and the epidemic emergence of HIV-2 in West Africa. PLoS One 11:e0166805. https://doi.org/10.1371/journal.pone.0166805.
20. de Sousa JD, Alvarez C, Vandamme A-M, Muller V. 2012. Enhanced heterosexual transmission hypothesis for the origin of pandemic HIV-1. Viruses 4:1950-1983. https://doi.org/10.3390/v4101950.
21. Kluge SF, Sauter D, Kirchhoff F. 2015. SnapShot: antiviral restriction factors. Cell 163:774-774.e1. https://doi.org/10.1016/j.cell.2015.10.019.
22. Colomer-Lluch M, Gollahon LS, Serra-Moreno R. 2016. Anti-HIV factors: targeting each step of HIV's replication cycle. Curr HIV Res 14:175-182. https://doi.org/10.2174/1570162X14999160224094621.
23. Neil SJD, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425-430. https://doi.org/ 10.1038/nature06553.
24. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, Stephens EB, Guatelli J. 2008. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3:245-252. https://doi.org/10.1016/j.chom.2008.03.001.
25. Zhang F, Wilson SJ, Landford WC, Virgen B, Gregory D, Johnson MC, Munch J, Kirchhoff F, Bieniasz PD, Hatziioannou T. 2009. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 6:54-67. https://doi.org/10.1016/j.chom.2009.05.008.
26. Sauter D, Schindler M, Specht A, Landford WN, Munch J, Kim K-A, Votteler J, Schubert U, Bibollet-Ruche F, Keele BF, Takehisa J, Ogando Y, Ochsenbauer C, Kappes JC, Ayouba A, Peeters M, Learn GH, Shaw G, Sharp PM, Bieniasz P, Hahn BH, Hatziioannou T, Kirchhoff F. 2009. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 6:409-421. https://doi.org/10.1016/j.chom.2009.10.004.
27. Yang SJ, Lopez LA, Hauser H, Exline CM, Haworth KG, Cannon PM. 2010. Anti-tetherin activities in Vpu-expressing primate lentiviruses. Retrovirology 7:13. https://doi.org/10.1186/1742-4690-7-13.
28. Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, Fofana IB, Johnson WE, Westmoreland S, Evans DT. 2009. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog 5:e1000429. https://doi.org/10.1371/journal.ppat.1000429.
29. Sauter D, Vogl M, Kirchhoff F. 2011. Ancient origin of a deletion in human BST2/Tetherin that confers protection against viral zoonoses. Hum Mutat 32:1243-1245. https://doi.org/10.1002/humu.21571.
30. Yang SJ, Lopez LA, Exline CM, Haworth KG, Cannon PM. 2011. Lack of adaptation to human tetherin in HIV-1 group O and P. Retrovirology 8:78. https://doi.org/10.1186/1742-4690-8-78.
31. Kluge SF, Mack K, Iyer SS, Pujol FM, Heigele A, Learn GH, Usmani SM, Sauter D, Joas S, Hotter D, Bibollet-Ruche F, Plenderleith LJ, Peeters M, Geyer M, Sharp PM, Fackler OT, Hahn BH, Kirchhoff F. 2014. Nef proteins of epidemic HIV-1 group O strains antagonize human tetherin. Cell Host Microbe 16:639-650. https://doi.org/10.1016/j.chom.2014.10.002.
32. Sauter D, Unterweger D, Vogl M, Usmani SM, Heigele A, Kluge SF, Hermkes E, Moll M, Barker E, Peeters M, Learn GH, Bibollet-Ruche F, Fritz JV, Fackler OT, Hahn BH, Kirchhoff F. 2012. Human tetherin exerts strong selection pressure on the HIV-1 group N Vpu protein. PLoS Pathog 8:e1003093. https://doi.org/10.1371/journal.ppat.1003093.
33. Sauter D, Hue S, Petit SJ, Plantier J-C, Towers GJ, Kirchhoff F, Gupta RK. 2011. HIV-1 group P is unable to antagonize human tetherin by Vpu, Env or Nef. Retrovirology 8:103. https://doi.org/10.1186/1742-4690-8-103.
34. Mack K, Starz K, Sauter D, Langer S, Bibollet-Ruche F, Learn GH, Sturzel CM, Leoz M, Plantier J-C, Geyer M, Hahn BH, Kirchhoff F. 2017. Efficient Vpu-mediated tetherin antagonism by an HIV-1 group O strain. J Virol 91:e02177-16. https://doi.org/10.1128/JVI.02177-16.
35. Sauter D, Specht A, Kirchhoff F. 2010. Tetherin: holding on and letting go. Cell 141:392-398. https://doi.org/10.1016/j.cell.2010.04.022.
36. Le Tortorec A, Neil SJD. 2009. Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J Virol 83:11966-11978. https://doi.org/10.1128/JVI.01515-09.
37. Hauser H, Lopez LA, Yang SJ, Oldenburg JE, Exline CM, Guatelli JC, Cannon PM. 2010. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology 7:51. https://doi.org/10.1186/1742-4690-7-51.
38. Chen C-Y, Shingai M, Welbourn S, Martin MA, Borrego P, Taveira N, Strebel K. 2016. Antagonism of BST-2/tetherin is a conserved function of the Env glycoprotein of primary HIV-2 isolates. J Virol 90: 11062-11074. https://doi.org/10.1128/JVI.01451-16.
39. Schindler M, Munch J, Kutsch O, Li H, Santiago ML, Bibollet-Ruche F, Muller-Trutwin MC, Novembre FJ, Peeters M, Courgnaud V, Bailes E, Roques P, Sodora DL, Silvestri G, Sharp PM, Hahn BH, Kirchhoff F. 2006. Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 125:1055-1067. https://doi.org/10.1016/j.cell.2006.04.033.
40. Khalid M, Yu H, Sauter D, Usmani SM, Schmokel J, Feldman J, Gruters RA, van der Ende ME, Geyer M, Rowland-Jones S, Osterhaus AD, Kirchhoff F. 2012. Efficient Nef-mediated downmodulation of TCR-CD3 and CD28 is associated with high CD4+ T cell counts in viremic HIV-2 infection. J Virol 86:4906-4920. https://doi.org/10.1128/JVI.06856-11.
41. Novembre FJ, De Rosayro J, O'Neil SP, Anderson DC, Klumpp SA, McClure HM. 1998. Isolation and characterization of a neuropathogenic simian immunodeficiency virus derived from a sooty mangabey. J Virol 72:8841-8851.
42. Schmokel J, Li H, Shabir A, Yu H, Geyer M, Silvestri G, Sodora DL, Hahn BH, Kirchhoff F. 2013. Link between primate lentiviral coreceptor usage and Nef function. Cell Rep 5:997-1009. https://doi.org/10.1016/j.celrep.2013.10.028.
43. Milush JM, Reeves JD, Gordon SN, Zhou D, Muthukumar A, Kosub DA, Chacko E, Giavedoni LD, Ibegbu CC, Cole KS, Miamidian JL, Paiardini M, Barry AP, Staprans SI, Silvestri G, Sodora DL. 2007. Virally induced CD4+ T cell depletion is not sufficient to induce AIDS in a natural host. J Immunol 179:3047-3056.
44. Fischer W, Apetrei C, Santiago ML, Li Y, Gautam R, Pandrea I, Shaw GM, Hahn BH, Letvin NL, Nabel GJ, Korber BT. 2012. Distinct evolutionary pressures underlie diversity in simian immunodeficiency virus and human immunodeficiency virus lineages. J Virol 86:13217-13231. https://doi.org/10.1128/JVI.01862-12.
45. Mansfield KG, Lerch NW, Gardner MB, Lackner AA. 1995. Origins of simian immunodeficiency virus infection in macaques at the New England Regional Primate Research Center. J Med Primatol 24:116-122. https://doi.org/10.1111/j.1600-0684.1995.tb00156.x.
46. Daniel MD, Letvin NL, King NW, Kannagi M, Sehgal PK, Hunt RD, Kanki PJ, Essex M, Desrosiers RC. 1985. Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science 228:1201-1204. https://doi.org/10.1126/science.3159089.
47. Clavel F, Guyader M, Guetard D, Salle M, Montagnier L, Alizon M. 1986. Molecular cloning and polymorphism of the human immune deficiency virus type 2. Nature 324:691-695. https://doi.org/10.1038/324691a0.
48. Ryan-Graham MA, Peden KW. 1995. Both virus and host components are important for the manifestation of a Nef-phenotype in HIV-1 and HIV-2. Virology 213:158-168. https://doi.org/10.1006/viro.1995.1556.
49. Clavel F, Guetard D, Brun-Vezinet F, Chamaret S, Rey MA, Santos-Ferreira MO, Laurent AG, Dauguet C, Katlama C, Rouzioux C. 1986. Isolation of a new human retrovirus from West African patients with AIDS. Science 233:343-346. https://doi.org/10.1126/science.2425430.
50. Kirchhoff F, Jentsch KD, Bachmann B, Stuke A, Laloux C, Luke W, Stahl-Hennig C, Schneider J, Nieselt K, Eigen M. 1990. A novel proviral clone of HIV-2: biological and phylogenetic relationship to other primate immunodeficiency viruses. Virology 177:305-311. https://doi.org/ 10.1016/0042-6822(90)90484-9.
51. Klemm E, Schneweis KE, Horn R, Tackmann W, Schulze G, Schneider J. 1988. HIV-II infection with initial neurological manifestation. J Neurol 235:304-307. https://doi.org/10.1007/BF00314179.
52. Barnett SW, Quiroga M, Werner A, Dina D, Levy JA. 1993. Distinguishing features of an infectious molecular clone of the highly divergent and noncytopathic human immunodeficiency virus type 2 UC1 strain. J Virol 67:1006-1014.
53. Evans LA, Moreau J, Odehouri K, Legg H, Barboza A, Cheng-Mayer C, Levy JA. 1988. Characterization of a noncytopathic HIV-2 strain with unusual effects on CD4 expression. Science 240:1522-1525.
54. Kuhnel H, Briesen H von, Dietrich U, Adamski M, Mix D, Biesert L, Kreutz R, Immelmann A, Henco K, Meichsner C. 1989. Molecular cloning of two west African human immunodeficiency virus type 2 isolates that replicate well in macrophages: a Gambian isolate, from a patient with neurologic acquired immunodeficiency syndrome, and a highly divergent Ghanian isolate. Proc Natl Acad Sci U S A 86:2383-2387.
55. Naidu YM, Kestler HW, Li Y, Butler CV, Silva DP, Schmidt DK, Troup CD, Sehgal PK, Sonigo P, Daniel MD. 1988. Characterization of infectious molecular clones of simian immunodeficiency virus (SIVmac) and human immunodeficiency virus type 2: persistent infection of rhesus monkeys with molecularly cloned SIVmac. J Virol 62:4691-4696.
56. Geyer M, Fackler OT, Peterlin BM. 2001. Structure-function relationships in HIV-1 Nef. EMBO Rep 2:580-585. https://doi.org/10.1093/embo-reports/kve141.
57. Manrique S, Sauter D, Horenkamp FA, Lulf S, Yu H, Hotter D, Anand K, Kirchhoff F, Geyer M. 2017. Endocytic sorting motif interactions involved in Nef-mediated downmodulation of CD4 and CD3. Nat Commun 8:442. https://doi.org/10.1038/s41467-017-00481-z.
58. Geyer M, Munte CE, Schorr J, Kellner R, Kalbitzer HR. 1999. Structure of the anchor-domain of myristoylated and non-myristoylated HIV-1 Nef protein. J Mol Biol 289:123-138. https://doi.org/10.1006/jmbi.1999.2740.
59. Saksela K, Cheng G, Baltimore D. 1995. Proline-rich (PxxP) motifs in HIV-1 Nef bind to SH3 domains of a subset of Src kinases and are required for the enhanced growth of Nef+ viruses but not for downregulation of CD4. EMBO J 14:484-491.
60. Bresnahan PA, Yonemoto W, Ferrell S, Williams-Herman D, Geleziunas R, Greene WC. 1998. A dileucine motif in HIV-1 Nef acts as an internalization signal for CD4 downregulation and binds the AP-1 clathrin adaptor. Curr Biol 8:1235-1238. https://doi.org/10.1016/ S0960-9822(07)00517-9.
61. Craig HM, Pandori MW, Guatelli JC. 1998. Interaction of HIV-1 Nef with the cellular dileucine-based sorting pathway is required for CD4 downregulation and optimal viral infectivity. Proc Natl Acad Sci U S A 95:11229-11234. https://doi.org/10.1073/pnas.95.19.11229.
62. Iafrate AJ, Carl S, Bronson S, Stahl-Hennig C, Swigut T, Skowronski J, Kirchhoff F. 2000. Disrupting surfaces of nef required for downregulation of CD4 and for enhancement of virion infectivity attenuates simian immunodeficiency virus replication in vivo. J Virol 74:9836-9844. https://doi.org/10.1128/JVI.74.21.9836-9844.2000.
63. Hallenberger S, Bosch V, Angliker H, Shaw E, Klenk HD, Garten W. 1992. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature 360:358-361. https://doi.org/10.1038/360358a0.
64. Molloy SS, Bresnahan PA, Leppla SH, Klimpel KR, Thomas G. 1992. Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen. J Biol Chem 267:16396-16402.
65. Rowell JF, Stanhope PE, Siliciano RF. 1995. Endocytosis of endogenously synthesized HIV-1 envelope protein. Mechanism and role in processing for association with class II MHC. J Immunol 155:473-488.
66. Bour S, Akari H, Miyagi E, Strebel K. 2003. Naturally occurring amino acid substitutions in the HIV-2 ROD envelope glycoprotein regulate its ability to augment viral particle release. Virology 309:85-98. https://doi.org/10.1016/S0042-6822(02)00128-9.
67. Dufrasne FE, Lombard C, Goubau P, Ruelle J. 2016. Single amino acid substitution N659D in HIV-2 envelope glycoprotein (Env) impairs viral release and hampers BST-2 antagonism. Viruses 8:E285. https://doi.org/ 10.3390/v8100285.
68. Howe AY, Jung JU, Desrosiers RC. 1998. Zeta chain of the T-cell receptor interacts with nef of simian immunodeficiency virus and human immunodeficiency virus type 2. J Virol 72:9827-9834.
69. Lama J, Mangasarian A, Trono D. 1999. Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef-and Vpu-inhibitable manner. Curr Biol 9:622-631. https://doi.org/10.1016/ S0960-9822(99)80284-X.
70. Benson RE, Sanfridson A, Ottinger JS, Doyle C, Cullen BR. 1993. Downregulation of cell-surface CD4 expression by simian immunodeficiency virus Nef prevents viral super infection. J Exp Med 177:1561-1566. https://doi.org/10.1084/jem.177.6.1561.
71. Miyagi E, Andrew AJ, Kao S, Strebel K. 2009. Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface downmodulation and intracellular depletion. Proc Natl Acad Sci U S A 106:2868-2873. https:// doi.org/10.1073/pnas.0813223106.
72. Schmokel J, Sauter D, Schindler M, Leendertz FH, Bailes E, Dazza M-C, Saragosti S, Bibollet-Ruche F, Peeters M, Hahn BH, Kirchhoff F. 2011. The presence of a vpu gene and the lack of Nef-mediated downmodulation of T cell receptor-CD3 are not always linked in primate lentiviruses. J Virol 85:742-752. https://doi.org/10.1128/JVI.02087-10.
73. Gupta RK, Mlcochova P, Pelchen-Matthews A, Petit SJ, Mattiuzzo G, Pillay D, Takeuchi Y, Marsh M, Towers GJ. 2009. Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc Natl Acad Sci U S A 106: 20889-20894. https://doi.org/10.1073/pnas.0907075106.
74. Lopez LA, Yang SJ, Hauser H, Exline CM, Haworth KG, Oldenburg J, Cannon PM. 2010. Ebola virus glycoprotein counteracts BST-2/tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J Virol 84:7243-7255. https://doi.org/10.1128/ JVI.02636-09.
75. Schmitt K, Mohan Kumar D, Curlin J, Remling-Mulder L, Stenglein M, O'Connor S, Marx P, Akkina R. 2017. Modeling the evolution of SIV sooty mangabey progenitor virus towards HIV-2 using humanized mice. Virology 510:175-184. https://doi.org/10.1016/j.virol.2017.07.005.
76. Aghokeng AF, Peeters M. 2005. Simian immunodeficiency viruses (SIVs) in Africa. J Neurovirol 11(Suppl 1):S27-S32.
77. Sharp PM, Hahn BH. 2011. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med 1:a006841. https://doi.org/10.1101/ cshperspect.a006841.
78. Apetrei C, Kaur A, Lerche NW, Metzger M, Pandrea I, Hardcastle J, Falkenstein S, Bohm R, Koehler J, Traina-Dorge V, Williams T, Staprans S, Plauche G, Veazey RS, McClure H, Lackner AA, Gormus B, Robertson DL, Marx PA. 2005. Molecular epidemiology of simian immunodeficiency virus SIVsm in U.S. primate centers unravels the origin of SIVmac and SIVstm. J Virol 79:8991-9005. https://doi.org/ 10.1128/JVI.79.14.8991-9005.2005.
79. Apetrei C, Gautam R, Sumpter B, Carter AC, Gaufin T, Staprans SI, Else J, Barnes M, Cao R, Garg S, Milush JM, Sodora DL, Pandrea I, Silvestri G. 2007. Virus subtype-specific features of natural simian immunodeficiency virus SIVsmm infection in sooty mangabeys. J Virol 81: 7913-7923. https://doi.org/10.1128/JVI.00281-07.
80. Abada P, Noble B, Cannon PM. 2005. Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production. J Virol 79:3627-3638. https://doi.org/10.1128/JVI.79.6.3627-3638.2005.
81. Noble B, Abada P, Nunez-Iglesias J, Cannon PM. 2006. Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release. J Virol 80:2924-2932. https://doi.org/10.1128/JVI.80.6.2924-2932.2006.
82. Serra-Moreno R, Jia B, Breed M, Alvarez X, Evans DT. 2011. Compensatory changes in the cytoplasmic tail of gp41 confer resistance to tetherin/BST-2 in a pathogenic nef-deleted SIV. Cell Host Microbe 9:46-57. https://doi.org/10.1016/j.chom.2010.12.005.
83. Matsuda K, Chen C-Y, Whitted S, Chertova E, Roser DJ, Wu F, Plishka RJ, Ourmanov I, Buckler-White A, Lifson JD, Strebel K, Hirsch VM. 2016. Enhanced antagonism of BST-2 by a neurovirulent SIV envelope. J Clin Investig 126:2295-2307. https://doi.org/10.1172/JCI83725.
84. Exline CM, Yang SJ, Haworth KG, Rengarajan S, Lopez LA, Droniou ME, Seclen E, Cannon PM. 2015. Determinants in HIV-2 Env and tetherin required for functional interaction. Retrovirology 12:67. https://doi.org/ 10.1186/s12977-015-0194-0.
85. Arias JF, Heyer LN, von Bredow B, Weisgrau KL, Moldt B, Burton DR, Rakasz EG, Evans DT. 2014. Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity. Proc Natl Acad Sci U S A 111:6425-6430. https://doi.org/10.1073/pnas.1321507111.
86. Alvarez RA, Hamlin RE, Monroe A, Moldt B, Hotta MT, Rodriguez Caprio G, Fierer DS, Simon V, Chen BK. 2014. HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells. J Virol 88:6031-6046. https://doi.org/10.1128/JVI.00449-14.
87. Galao RP, Le Tortorec A, Pickering S, Kueck T, Neil SJD. 2012. Innate sensing of HIV-1 assembly by tetherin induces NFκB-dependent proinflammatory responses. Cell Host Microbe 12:633-644. https://doi.org/10.1016/j.chom.2012.10.007.
88. Kmiec D, Iyer SS, Sturzel CM, Sauter D, Hahn BH, Kirchhoff F. 2016. Vpu-mediated counteraction of tetherin is a major determinant of HIV-1 interferon resistance. mBio 7:e00934-16. https://doi.org/10.1128/ mBio.00934-16.
89. Yamada E, Nakaoka S, Klein L, Reith E, Langer S, Hopfensperger K, Iwami S, Schreiber G, Kirchhoff F, Koyanagi Y, Sauter D, Sato K. 2018. Human-specific adaptations in Vpu conferring anti-tetherin activity are critical for efficient early HIV-1 replication in vivo. Cell Host Microbe 23:110-120. https://doi.org/10.1016/j.chom.2017.12.009.
90. Pickering S, Hue S, Kim E-Y, Reddy S, Wolinsky SM, Neil SJD. 2014. Preservation of tetherin and CD4 counter-activities in circulating Vpu alleles despite extensive sequence variation within HIV-1 infected individuals. PLoS Pathog 10:e1003895. https://doi.org/10.1371/journal.ppat.1003895.
91. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P. 2009. Tetherinmediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci U S A 106:2886-2891. https://doi.org/ 10.1073/pnas.0811014106.
92. Kuhl A, Banning C, Marzi A, Votteler J, Steffen I, Bertram S, Glowacka I, Konrad A, Sturzl M, Guo J-T, Schubert U, Feldmann H, Behrens G, Schindler M, Pohlmann S. 2011. The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin. J Infect Dis 204(Suppl 3):S850-S860. https://doi.org/ 10.1093/infdis/jir378.
93. Gnirs K, Zmora P, Blazejewska P, Winkler M, Lins A, Nehlmeier I, Gartner S, Moldenhauer A-S, Hofmann-Winkler H, Wolff T, Schindler M, Pohlmann S. 2015. Tetherin sensitivity of influenza A viruses is strain specific: role of hemagglutinin and neuraminidase. J Virol 89: 9178-9188. https://doi.org/10.1128/JVI.00615-15.
94. Morrison JH, Guevara RB, Marcano AC, Saenz DT, Fadel HJ, Rogstad DK, Poeschla EM. 2014. Feline immunodeficiency virus envelope glycoproteins antagonize tetherin through a distinctive mechanism that requires virion incorporation. J Virol 88:3255-3272. https://doi.org/10.1128/JVI.03814-13.
95. Lemaitre C, Harper F, Pierron G, Heidmann T, Dewannieux M. 2014. The HERV-K human endogenous retrovirus envelope protein antagonizes Tetherin antiviral activity. J Virol 88:13626-13637. https://doi.org/10.1128/JVI.02234-14.
96. Liu Y, Luo S, He S, Zhang M, Wang P, Li C, Huang W, Hu B, Griffin GE, Shattock RJ, Hu Q. 2015. Tetherin restricts HSV-2 release and is counteracted by multiple viral glycoproteins. Virology 475:96-109. https:// doi.org/10.1016/j.virol.2014.11.005.
97. Yin X, Hu Z, Gu Q, Wu X, Zheng Y-H, Wei P, Wang X. 2014. Equine tetherin blocks retrovirus release and its activity is antagonized by equine infectious anemia virus envelope protein. J Virol 88:1259-1270. https://doi.org/10.1128/JVI.03148-13.
98. Jolly C, Booth NJ, Neil SJD. 2010. Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. J Virol 84:12185-12199. https://doi.org/10.1128/JVI.01447-10.
99. Liang Z, Zhang Y, Song J, Zhang H, Zhang S, Li Y, Tan J, Qiao W. 2017. The effect of bovine BST2A1 on the release and cell-to-cell transmission of retroviruses. Virol J 14:173. https://doi.org/10.1186/ s12985-017-0835-0.
100. Kanki PJ, Travers KU, Mboup S, Hsieh CC, Marlink RG, Gueye-Ndiaye A, Siby T, Thior I, Hernandez-Avila M, Sankale JL. 1994. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 343:943-946. https://doi.org/10.1016/S0140-6736(94)90065-5.
101. Heigele A, Kmiec D, Regensburger K, Langer S, Peiffer L, Sturzel CM, Sauter D, Peeters M, Pizzato M, Learn GH, Hahn BH, Kirchhoff F. 2016. The potency of Nef-mediated SERINC5 antagonism correlates with the prevalence of primate lentiviruses in the wild. Cell Host Microbe 20: 381-391. https://doi.org/10.1016/j.chom.2016.08.004.
102. Gotz N, Sauter D, Usmani SM, Fritz JV, Goffinet C, Heigele A, Geyer M, Bibollet-Ruche F, Learn GH, Fackler OT, Hahn BH, Kirchhoff F. 2012. Reacquisition of Nef-mediated tetherin antagonism in a single in vivo passage of HIV-1 through its original chimpanzee host. Cell Host Microbe 12:373-380. https://doi.org/10.1016/j.chom.2012.07.008.
103. DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, Calos MP. 1987. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 7:379-387. https://doi.org/10.1128/MCB.7.1.379.
104. Scherer WF, Syverton JT, Gey GO. 1953. Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. J Exp Med 97:695-710.
105. Casartelli N, Sourisseau M, Feldmann J, Guivel-Benhassine F, Mallet A, Marcelin A-G, Guatelli J, Schwartz O. 2010. Tetherin restricts productive HIV-1 cell-to-cell transmission. PLoS Pathog 6:e1000955. https://doi.org/10.1371/journal.ppat.1000955.
106. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72: 2855-2864.
107. Schmokel J, Li H, Bailes E, Schindler M, Silvestri G, Hahn BH, Apetrei C, Kirchhoff F. 2009. Conservation of Nef function across highly diverse lineages of SIVsmm. Retrovirology 6:36. https://doi.org/10.1186/1742-4690-6-36.
108. Schindler M, Schmokel J, Specht A, Li H, Munch J, Khalid M, Sodora DL, Hahn BH, Silvestri G, Kirchhoff F. 2008. Inefficient Nef-mediated downmodulation of CD3 and MHC-I correlates with loss of CD4+ T cells in natural SIV infection. PLoS Pathog 4:e1000107. https://doi.org/10.1371/ journal.ppat.1000107.
109. de Silva TI, Aasa-Chapman M, Cotten M, Hue S, Robinson J, Bibollet-Ruche F, Sarge-Njie R, Berry N, Jaye A, Aaby P, Whittle H, Rowland-Jones S, Weiss R. 2012. Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes. J Virol 86:930-946. https://doi.org/10.1128/JVI.06126-11.
110. Schindler M, Munch J, Kirchhoff F. 2005. Human immunodeficiency virus type 1 inhibits DNA damage-triggered apoptosis by a Nefindependent mechanism. J Virol 79:5489-5498. https://doi.org/10.1128/JVI.79.9.5489-5498.2005.
111. Kong R, Li H, Georgiev I, Changela A, Bibollet-Ruche F, Decker JM, Rowland-Jones SL, Jaye A, Guan Y, Lewis GK, Langedijk JPM, Hahn BH, Kwong PD, Robinson JE, Shaw GM. 2012. Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies. J Virol 86: 12115-12128. https://doi.org/10.1128/JVI.01632-12.
112. Kong R, Li H, Bibollet-Ruche F, Decker JM, Zheng NN, Gottlieb GS, Kiviat NB, Sow PS, Georgiev I, Hahn BH, Kwong PD, Robinson JE, Shaw GM. 2012. Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection. J Virol 86:947-960. https://doi.org/10.1128/JVI.06155-11.
113. Decker JM, Bibollet-Ruche F, Wei X, Wang S, Levy DN, Wang W, Delaporte E, Peeters M, Derdeyn CA, Allen S, Hunter E, Saag MS, Hoxie JA, Hahn BH, Kwong PD, Robinson JE, Shaw GM. 2005. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 201:1407-1419. https://doi.org/10.1084/jem.20042510.
114. Tanaka M, Herr W. 1990. Differential transcriptional activation by Oct-1 and Oct-2: interdependent activation domains induce Oct-2 phosphorylation. Cell 60:375-386. https://doi.org/10.1016/0092-8674(90)90589-7.
115. McNatt MW, Zang T, Hatziioannou T, Bartlett M, Fofana IB, Johnson WE, Neil SJD, Bieniasz PD. 2009. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog 5:e1000300. https://doi.org/10.1371/journal.ppat.1000300.
116. Fouchier RA, Meyer BE, Simon JH, Fischer U, Malim MH. 1997. HIV-1 infection of non-dividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import. EMBO J 16:4531-4539. https://doi.org/10.1093/emboj/16.15.4531.
117. Ehrhardt C, Schmolke M, Matzke A, Knoblauch A, Will C, Wixler V, Ludwig S. 2006. Polyethylenimine, a cost-effective transfection reagent. Signal Transduct 6:179-184. https://doi.org/10.1002/sita.200500073.
118. Corpet F. 1988. Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res 16:10881-10890. https://doi.org/10.1093/nar/16.22.10881.
119. Schaefer TM, Bell I, Pfeifer ME, Ghosh M, Trible RP, Fuller CL, Ashman C, Reinhart TA. 2002. The conserved process of TCR/CD3 complex downmodulation by SIV Nef is mediated by the central core, not endocytic motifs. Virology 302:106-122. https://doi.org/10.1006/ viro.2002.1628.
120. Chesebro B, Wehrly K, Nishio J, Perryman S. 1992. Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism. J Virol 66:6547-6554.
121. Smith SM, Marx PA. November 2009. Pathogenic west african human immunodeficiency virus type 2 (HIV-2) group F isolate. US patent 8,747,862.